The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol

BMC Cancer

Study Protocol

Livia Giordano¹  Nereo Segnan¹  Federica Gallo¹  Giovanna Chiorino²  Elisabetta Petracci³ 

[1] Centre for Cancer Prevention (CPO Piemonte), Unit of Epidemiology and Screening, AOU Città della Salute e della Scienza of Turin, Via Cavour 31, 10123, Turin, Italy;Edo & Elvo Tempia Foundation, Biella, Italy;Unity of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, IRCCS, Meldola, Italy;

关键词: Breast cancer;    Tailored screening;    Risk prediction models;   

DOI  :  10.1186/s12885-017-3784-5

 received in 2017-08-04, accepted in 2017-11-13,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundIn recent years growing interest has been posed on alternative ways to screen women for breast cancer involving different imaging techniques or adjusting screening interval by breast cancer risk estimates. A new research area is studying circulating microRNAs as molecular biomarkers potentially useful for non invasive early detection together with the analysis of single-nucleotide polymorphisms (SNPs).The Andromeda study is a prospective cohort study on women attending breast cancer screening in a northern Italian area. The aims of the study are: 1) to define appropriate women risk-based stratifications for personalized screening considering different factors (reproductive, family and biopsy history, breast density, lifestyle habits); 2) to evaluate the diagnostic accuracy of selected circulating microRNAs in a case-control study nested within the above mentioned cohort.MethodsAbout 21,000 women aged 46–67 years compliant to screening mammography are expected to be enrolled. At enrolment, information on well-known breast cancer risk factors and life-styles habits are collected through self-admistered questionnaires. Information on breast density and anthropometric measurements (height, weight, body composition, and waist circumference) are recorded. In addition, women are requested to provide a blood sample for serum, plasma and buffy-coat storing for subsequent molecular analyses within the nested case-control study. This investigation will be performed on approximately 233 cases (screen-detected) and 699 matched controls to evaluate SNPs and circulating microRNAs. The whole study will last three years and the cohort will be followed up for ten years to observe the onset of new breast cancer cases.DiscussionNowadays women undergo the same screening protocol, independently of their breast density and their individual risk to develop breast cancer. New criteria to better stratify women in risk groups could enable the screening strategies to target high-risk women while reducing interventions in those at low-risk. In this frame the present study will contribute in identifying the feasibility and impact of implementing personalized breast cancer screening.Trial registrationNCT02618538 (retrospectively registered on 27–11-2015.)

【 授权许可】

CC BY   
© The Author(s). 2017